Related Experiment Video
Updated: Jan 12, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Circulating Glioma Model for Chimeric Antigen Receptor T-Cell Therapy Investigations
Yuhan Zhang1, Shuo Sun2, Hongyi Liu3
1School of Chemistry and Chemical Engineering, Southeast University; Department of Immunology, Key Laboratory of Human Functional Genomics of Jiangsu Province, Gusu School, Nanjing Medical University.
Abstract:
Circulating tumor cells in cerebrospinal fluid (CSF) are a significant factor in tumor recurrence and intracranial metastasis in glioma. Many studies are attempting to identify effective strategies to target and eliminate the circulating tumor in CSF. Chimeric antigen receptor (CAR) T-cell therapy has been frequently used for various circulating tumors. However, research is limited due to the lack of a suitable circulating glioma model. Here, a circulating glioma model was developed and applied in CAR T-cell therapy investigations. This model was constructed using the lateral ventricle injection, which is widely used in the local treatment of intracranial disease. The glioma cells were injected into the lateral ventricle to form the intracranial primary tumor. The tumors that were shed from the lateral ventricle were used to indicate the circulating tumor in CSF. The model is easy to build and can be applied in various studies on the CAR T-cell therapy of circulating glioma. As a result, the circulating glioma model provides a unique glioma metastasis model for effective CAR T-cell therapy studies of the circulating tumor.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015